Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Deferasirox may be effective in treating iron overload caused by blood
transfusions in patients who have undergone donor stem cell transplant.
PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in
treating patients with iron overload after donor stem cell transplant.